Skip to main content

Advertisement

Log in

Prevalence, pathogenesis, and treatment options for mastocytosis-related osteoporosis

  • Review
  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

Mastocytosis is a rare condition characterized by abnormal mast cell proliferation and a broad spectrum of manifestations, including various organs and tissues. Osteoporosis is one of the most frequent manifestations of systemic mastocytosis, particularly in adults. Osteoporosis secondary to systemic mastocytosis is a cause of unexplained low bone mineral density that should be investigated when accompanied by suspicious clinical elements. Bone involvement is often complicated by a high recurrence of fragility fractures, mainly vertebral, leading to severe disability. The mechanism of bone loss is the result of different pathways, not yet fully discovered. The main actor is the osteoclast with a relative or absolute predominance of bone resorption. Among the stimuli that drive osteoclast activity, the most important one seems to be the RANK-RANKL signaling, but also histamine and other cytokines play a significant role in the process. The central role of osteoclasts made bisphosphonates, as anti-resorptive drugs, the most rational treatment for bone involvement in systemic mastocytosis. There are a few small studies supporting this approach, with large heterogeneity of drug and administration scheme. Currently, zoledronate has the best evidence in terms of gain in bone mineral density and bone turnover suppression, two surrogate markers of anti-fracture efficacy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Krishnaswamy G, Ajitawi O, Chi DS (2006) The human mast cell: an overview. Methods Mol Biol 315:13–34

    PubMed  Google Scholar 

  2. Arock M, Valent P (2010) Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives. Expert Rev Hematol 3:497–516

    Article  PubMed  Google Scholar 

  3. Valent P (1994) The riddle of the mast cell: kit(CD117)-ligand as the missing link? Immunol Today 15:111–114

    Article  CAS  PubMed  Google Scholar 

  4. Kirshenbaum AS, Goff JP, Semere T, Foster B, Scott LM, Metcalfe DD (1999) Demonstration that human mast cells arise from a progenitor cell population that is CD34(+), c-kit(+), and expresses aminopeptidase N (CD13). Blood 94:2333–2342

    CAS  PubMed  Google Scholar 

  5. Fried AJ, Akin C (2013) Primary mast cell disorders in children. Curr Allergy Asthma Rep 13:693–701

    Article  CAS  PubMed  Google Scholar 

  6. Sperr WR, Valent P (2012) Diagnosis, progression patterns and prognostication in mastocytosis. Expert Rev Hematol 5:261–274

    Article  CAS  PubMed  Google Scholar 

  7. Valent P (2013) Mastocytosis: a paradigmatic example of a rare disease with complex biology and pathology. Am J Cancer Res 3:159–172

    PubMed  PubMed Central  Google Scholar 

  8. Lee JK, Whittaker SJ, Enns RA, Zetler P (2008) Gastrointestinal manifestations of systemic mastocytosis. World J Gastroenterol 14:7005–7008

    Article  PubMed  PubMed Central  Google Scholar 

  9. Pardanani A (2013) Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification, and management. Am J Hematol 88:612–624

    Article  CAS  PubMed  Google Scholar 

  10. Stoecker MM, Wang E (2012) Systemic mastocytosis with associated clonal hematologic nonmast cell lineage disease: a clinicopathologic review. Arch Pathol Lab Med 136:832–838

    Article  PubMed  Google Scholar 

  11. Valent P, Sperr WR, Akin C (2010) How I treat patients with advanced systemic mastocytosis. Blood 116:5812–5817

    Article  CAS  PubMed  Google Scholar 

  12. George TI, Horny HP (2011) Systemic mastocytosis. Hematol Oncol Clin North Am 25:1067–1083

    Article  PubMed  Google Scholar 

  13. Sokol H, Georgin-Lavialle S, Canioni D et al (2013) Gastrointestinal manifestations in mastocytosis: a study of 83 patients. J Allergy Clin Immunol 132:866–873 e1–3

    Article  PubMed  Google Scholar 

  14. Rossini M, Zanotti R, Viapiana O, Tripi G, Orsolini G, Idolazzi L, Bonadonna P, Schena D, Escribano L, Adami S, Gatti D (2014) Bone involvement and osteoporosis in mastocytosis. Immunol Allergy Clin North Am 34:383–396

    Article  PubMed  Google Scholar 

  15. Valent P, Akin C, Escribano L, Födinger M, Hartmann K, Brockow K, Castells M, Sperr WR, Kluin-Nelemans HC, Hamdy NA, Lortholary O, Robyn J, van Doormaal J, Sotlar K, Hauswirth AW, Arock M, Hermine O, Hellmann A, Triggiani M, Niedoszytko M, Schwartz LB, Orfao A, Horny HP, Metcalfe DD (2007) Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 37:435–453

    Article  CAS  PubMed  Google Scholar 

  16. Zanotti R, Lombardo C, Passalacqua G, Caimmi C, Bonifacio M, De Matteis G, Perbellini O, Rossini M, Schena D, Busa M, Marcotulli MC, Bilò MB, Franchini M, Marchi G, Simioni L, Bonadonna P (2015) Clonal mast cell disorders in patients with severe Hymenoptera venom allergy and normal serum tryptase levels. J Allergy Clin Immunol 136:135–139

    Article  CAS  PubMed  Google Scholar 

  17. Kanis JA (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO study Group. Osteoporos Int 4:368–381

    Article  CAS  PubMed  Google Scholar 

  18. Escribano L, Alvarez-Twose I, Sánchez-Muñoz L, Garcia-Montero A, Núñez R, Almeida J, Jara-Acevedo M, Teodósio C, García-Cosío M, Bellas C, Orfao A (2009) Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients. J Allergy Clin Immunol 124:514–521

    Article  PubMed  Google Scholar 

  19. Barete S, Assous N, de Gennes C, Granpeix C, Feger F, Palmerini F et al (2010) Systemic mastocytosis and bone involvement in a cohort of 75 patients. Ann Rheum Dis 69:1838–1841

    Article  CAS  PubMed  Google Scholar 

  20. Rossini M, Zanotti R, Bonadonna P, Artuso A, Caruso B, Schena D, Vecchiato D, Bonifacio M, Viapiana O, Gatti D, Senna G, Riccio A, Passalacqua G, Pizzolo G, Adami S (2011) Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis. Bone 49:880–885

    Article  PubMed  Google Scholar 

  21. van der Veer E, van der Goot W, de Monchy JG, Kluin-Nelemans HC, van Doormaal JJ (2012) High prevalence of fractures and osteoporosis in patients with indolent systemic mastocytosis. Allergy 67:431–438

    Article  PubMed  Google Scholar 

  22. Lewiecki EM, Gordon CM, Baim S, Leonard MB, Bishop NJ, Bianchi ML (2008) International society for clinical densitometry 2007 adult and pediatric official positions. Bone 43:1115–1121

    Article  PubMed  Google Scholar 

  23. Hermine O, Lortholary O, Leventhal PS, Catteau A, Soppelsa F, Baude C, Cohen-Akenine A, Palmérini F, Hanssens K, Yang Y, Sobol H, Fraytag S, Ghez D, Suarez F, Barete S, Casassus P, Sans B, Arock M, Kinet JP, Dubreuil P, Moussy A (2008) Case–control cohort study of patients’ perceptions of disability in mastocytosis. PLoS One 3(5):e2266

    Article  PubMed  PubMed Central  Google Scholar 

  24. Cohen SS, Skovbo S, Vestergaard H, Kristensen T, Møller M, Bindslev-Jensen C, Fryzek JP, Broesby-Olsen S (2014) Epidemiology of systemic mastocytosis in Denmark. Br J Haematol 166:521–528

    Article  PubMed  Google Scholar 

  25. van der Veer E, Arends S, van der Hoek S, Versluijs JB, de Monchy JG, Oude Elberink JN, van Doormaal JJ (2014) Predictors of new fragility fractures after diagnosis of indolent systemic mastocytosis. J Allergy Clin Immunol 134:1413–1421

    Article  PubMed  Google Scholar 

  26. Fallon MD, Whyte MP, Teitelbaum SL (1981) Systemic mastocytosis associated with generalized osteopenia. Histopathological characterization of the skeletal lesion using undecalcified bone from two patients. Hum Pathol 12:813–820

    Article  CAS  PubMed  Google Scholar 

  27. Chines A, Pacifici R, Avioli LV, Teitelbaum SL, Korenblat PE (1991) Systemic mastocytosis presenting as osteoporosis: a clinical and histomorphometric study. J Clin Endocrinol Metab 72:140–144

    Article  CAS  PubMed  Google Scholar 

  28. Seitz S, Barvencik F, Koehne T, Priemel M, Pogoda P, Semler J, Minne H, Pfeiffer M, Zustin J, Püschel K, Eulenburg C, Schinke T, Amling M (2013) Increased osteoblast and osteoclast indices in individuals with systemic mastocytosis. Osteoporos Int 24:2325–2334

    Article  CAS  PubMed  Google Scholar 

  29. De Gennes C, Kuntz D, de Vernejoul MC (1992) Bone mastocytosis. A report of nine cases with a bone histomorphometric study. Clin Orthop Relat Res 279:281–291

    PubMed  Google Scholar 

  30. Delling G, Ritzel H, Werner M (2001) Histological characteristics and prevalence of secondary osteoporosis in systemic mastocytosis. A retrospective analysis of 158 cases. Pathologe 22:132–140

    Article  CAS  PubMed  Google Scholar 

  31. Metcalfe DD (2008) Mast cells and mastocytosis. Blood 112:946–955

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Schwartz LB (1987) Mediators of human mast cells and human mast cell subsets. Ann Allergy 58:226–235

    CAS  PubMed  Google Scholar 

  33. Macpherson JL, Kemp A, Rogers M, Mallet AI, Toia RF, Spur B, Earl JW, Chesterman CN, Krilis SA (1989) Occurrence of platelet-activating factor (PAF) and an endogenous inhibitor of platelet aggregation in diffuse cutaneous mastocytosis. Clin Exp Immunol 77:391–396

    CAS  PubMed  PubMed Central  Google Scholar 

  34. Theoharides TC, Boucher W, Spear K (2002) Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol 128:344–350

    Article  CAS  PubMed  Google Scholar 

  35. Brockow K, Akin C, Huber M, Metcalfe DD (2005) IL-6 levels predict disease variant and extent of organ involvement in patients with mastocytosis. Clin Immunol 115:216–223

    Article  CAS  PubMed  Google Scholar 

  36. Chiappetta N, Gruber B (2006) The role of mast cells in osteoporosis. Semin Arthritis Rheum 36:32–36

    Article  CAS  PubMed  Google Scholar 

  37. Galli SJ, Tsai M (2008) Mast cells: versatile regulators of inflammation, tissue remodeling, host defense and homeostasis. J Dermatol Sci 49:7–19

    Article  CAS  PubMed  Google Scholar 

  38. Dobigny C, Saffar JL (1997) H1 and H2 histamine receptors modulate osteoclastic resorption by different pathways: evidence obtained by using receptor antagonists in a rat synchronized resorption model. J Cell Physiol 173:10–18

    Article  CAS  PubMed  Google Scholar 

  39. Biosse-Duplan M, Baroukh B, Dy M, de Vernejoul MC, Saffar JL (2009) Histamine promotes osteoclastogenesis through the differential expression of histamine receptors on osteoclasts and osteoblasts. Am J Pathol 174:1426–1434

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Fitzpatrick LA, Buzas E, Gagne TJ, Nagy A, Horvath C, Ferencz V et al (2003) Targeted deletion of histamine decarboxylase gene in mice increases bone formation and protects against ovariectomy-induced bone loss. Proc Natl Acad Sci U S A 100:6027–6032

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Escribano L, Akin C, Castells M, Schwartz LB (2006) Current options in the treatment of mast cell mediator-related symptoms in mastocytosis. Inflamm Allergy Drug Targets 5:61–77

    Article  CAS  PubMed  Google Scholar 

  42. Worobec AS, Metcalfe DD (2002) Mastocytosis: current treatment concepts. Int Arch Allergy Immunol 127:153–155

    Article  PubMed  Google Scholar 

  43. Lytinas M, Kempuraj D, Huang M et al (2002) Azelastine’s inhibition of histamine and tryptase release from human umbilical cord blood-derived cultured mast cells as well as rat skin mast cell-induced vascular permeability: comparison with olopatadine. Allergy Asthma Proc 23:45–51

    CAS  PubMed  Google Scholar 

  44. Hadzijusufovic E, Peter B, Gleixner KV, Schuch K, Pickl WF, Thaiwong T, Yuzbasiyan-Gurkan V, Mirkina I, Willmann M, Valent P (2010) H1-receptor antagonists terfenadine and loratadine inhibit spontaneous growth of neoplastic mast cells. Exp Hematol 38:896–907

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Turner PJ, Kemp AS, Rogers M, Mehr S (2012) Refractory symptoms successfully treated with leukotriene inhibition in a child with systemic mastocytosis. Pediatr Dermatol 29:222–223

    Article  PubMed  Google Scholar 

  46. Mullol J, Bousquet J, Bachert C, Canonica GW, GimenezArnau A, Kowalski ML, Simons FE, Maurer M, Ryan D, Scadding G (2015) Update on rupatadine in the management of allergic disorders. Allergy 70(suppl 100):1–24

    Article  CAS  PubMed  Google Scholar 

  47. Guillaume N, Desoutter J, Chandesris O, Merlusca L, Henry I, Georgin-Lavialle S, Barete S, Hirsch I, Bouredji D, Royer B, Gruson B, Lok C, Sevestre H, Mentaverri R, Brazier M, Meynier J, Hermine O, Marolleau JP, Kamel S, Damaj G (2013) Bone complications of mastocytosis: a link between clinical and biological characteristics. Am J Med 126:75.e1

    Article  CAS  Google Scholar 

  48. Rabenhorst A, Christopeit B, Leja S, Gerbaulet A, Kleiner S, Förster A, Raap U, Wickenhauser C, Hartmann K (2013) Serum levels of bone cytokines are increased in indolent systemic mastocytosis associated with osteopenia or osteoporosis. J Allergy Clin Immunol 132:1234–1237

    Article  CAS  PubMed  Google Scholar 

  49. Ali AS, Lax AS, Liljestrom M, Paakkari I, Ashammakhi N, Kovanen PT, Konttinen YT (2006) Mast cells in atherosclerosis as a source of the cytokine RANKL. Clin Chem Lab Med 44:672–674

    CAS  PubMed  Google Scholar 

  50. Rossini M, Gatti D, Adami S (2013) Involvement of WNT/β-catenin signaling in the treatment of osteoporosis. Calcif Tissue Int 93:121–132

    Article  CAS  PubMed  Google Scholar 

  51. Rossini M, Viapiana O, Zanotti R, Tripi G, Perbellini O, Idolazzi L, Bonifacio M, Adami S, Gatti D (2015) Dickkopf-1 and sclerostin serum levels in patients with systemic mastocytosis. Calcif Tissue Int 96:410–416

    Article  CAS  PubMed  Google Scholar 

  52. Rossini M, Adami S, Zanotti R, Viapiana O, Idolazzi L, Biondan M, Gatti D (2014) Serum levels of bone cytokines in indolent systemic mastocytosis associated with osteopenia or osteoporosis. J Allergy Clin Immunol 133:933–935

    Article  CAS  PubMed  Google Scholar 

  53. Cundy T, Beneton MN, Darby AJ, Marshall WJ, Kanis JA (1987) Osteopenia in systemic mastocytosis: natural history and responses to treatment with inhibitors of bone resorption. Bone 8:149–155

    Article  CAS  PubMed  Google Scholar 

  54. Marshall A, Kavanagh RT, Crisp AJ (1997) The effect of pamidronate on lumbar spine bone density and pain in osteoporosis secondary to systemic mastocytosis. Br J Rheumatol 36:393–396

    Article  CAS  PubMed  Google Scholar 

  55. Brumsen C, Hamdy NA, Papapoulos SE (2002) Osteoporosis and bone marrow mastocytosis: dissociation of skeletal responses and mast cell activity during long-term bisphosphonate therapy. J Bone Miner Res 17:567–569

    Article  PubMed  Google Scholar 

  56. Lim AY, Ostor AJ, Love S, Crisp AJ (2005) Systemic mastocytosis: a rare cause of osteoporosis and its response to bisphosphonate treatment. Ann Rheum Dis 64:965–966

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Laroche M, Bret J, Brouchet A, Maziéres B (2007) Clinical and densitometric efficacy of the association of interferon alpha and pamidronate in the treatment of osteoporosis in patients with systemic mastocytosis. Clin Rheumatol 26:242–243

    Article  CAS  PubMed  Google Scholar 

  58. Laroche M, Livideanu C, Paul C, Cantagrel A (2011) Interferon alpha and pamidronate in osteoporosis with fracture secondary to mastocytosis. Am J Med 124:776–778

    Article  CAS  PubMed  Google Scholar 

  59. Rossini M, Zanotti R, Viapiana O, Tripi G, Idolazzi L, Biondan M, Orsolini G, Bonadonna P, Adami S, Gatti D (2014) Zoledronic acid in osteoporosis secondary to mastocytosis. Am J Med 127:1127.e1–4

    Article  CAS  Google Scholar 

  60. Grey A, Bolland MJ, Horne A, Wattie D, House M, Gamble G, Reid IR (2012) Five years of anti-resorptive activity after a single dose of zoledronate—results from a randomized double-blind placebo-controlled trial. Bone 50:1389–1393

    Article  CAS  PubMed  Google Scholar 

  61. Reid IR, Black DM, Eastell R, Bucci-Rechtweg C, Su G, Hue TF, Mesenbrink P, Lyles KW, Boonen S (2013) Reduction in the risk of clinical fractures after a single dose of zoledronic acid 5 milligrams. J Clin Endocrinol Metab 98:557–563

    Article  CAS  PubMed  Google Scholar 

  62. Rossini M, Adami G, Adami S, Viapiana O, Gatti D (2016) Safety issues and adverse reactions with osteoporosis management. Expert Opin Drug Saf 14:1–12

    Google Scholar 

  63. Weide R, Ehlenz K, Lorenz W, Walthers E, Klausmann M, Pfluger KH (1996) Successful treatment of osteoporosis in systemic mastocytosis with interferon alpha-2b. Ann Hematol 72:41–43

    Article  CAS  PubMed  Google Scholar 

  64. Lehmann T, Beyeler C, Lämmle B et al (1996) Severe osteoporosis due to systemic mast cell disease: successful treatment with interferon alpha-2B. Br J Rheumatol 35:898–900

    Article  CAS  PubMed  Google Scholar 

  65. Butterfield JH (2005) Interferon treatment for hypereosinophilic syndromes and systemic mastocytosis. Acta Haematol 114:26–40

    Article  CAS  PubMed  Google Scholar 

  66. Valent P, Escribano L, Broesby-Olsen S, Hartmann K, Grattan C, Brockow K, Niedoszytko M, Nedoszytko B, Oude Elberink JN, Kristensen T, Butterfield JH, Triggiani M, Alvarez-Twose I, Reiter A, Sperr WR, Sotlar K, Yavuz S, Kluin-Nelemans HC, Hermine O, Radia D, van Doormaal JJ, Gotlib J, Orfao A, Siebenhaar F, Schwartz LB, Castells M, Maurer M, Horny HP, Akin C, Metcalfe DD, Arock M (2014) Proposed diagnostic algorithm for patients with suspected mastocytosis: a proposal of the European Competence Network on Mastocytosis. Allergy 69:1267–1274

    Article  CAS  PubMed  Google Scholar 

  67. Chen CC, Andrich MP, Mican JM, Metcalfe DD (1994) A retrospective analysis of bone scan abnormalities in mastocytosis: correlation with disease category and prognosis. J Nucl Med 35:1471–1475

    CAS  PubMed  Google Scholar 

  68. Turner RT, Iwaniec UT, Marley K, Sibonga JD (2010) The role of mast cells in parathyroid bone disease. J Bone Miner Res 25:1637–1649

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Pardanani A (2013) How I treat patients with indolent and smoldering mastocytosis (rare conditions but difficult to manage). Blood 121:3085–3094

    Article  CAS  PubMed  Google Scholar 

  70. Tefferi A, Li CY, Butterfield JH, Hoagland HC (2001) Treatment of systemic mast-cell disease with cladribine. N Engl J Med 344:307–309

    Article  CAS  PubMed  Google Scholar 

  71. Verstovsek S (2013) Advanced systemic mastocytosis: the impact of KIT mutations in diagnosis, treatment, and progression. Eur J Haematol 90:89–98

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Graves L 3rd, Stechschulte DJ, Morris DC, Lukert BP (1990) Inhibition of mediator release in systemic mastocytosis is associated with reversal of bone changes. J Bone Miner Res 5:1113–1119

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

The authors thank Sara Rossini who provided editorial assistance.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to M. Rossini.

Ethics declarations

Conflicts of interest

None.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rossini, M., Zanotti, R., Orsolini, G. et al. Prevalence, pathogenesis, and treatment options for mastocytosis-related osteoporosis. Osteoporos Int 27, 2411–2421 (2016). https://doi.org/10.1007/s00198-016-3539-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-016-3539-1

Keywords

Navigation